A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
{{output}}
Background: Ritlecitinib, a JAK3/TEC family kinase inhibitor, and baricitinib, a JAK1/2 inhibitor, are approved for treating severe alopecia areata (AA). Objectiv... ...
